Sickle Cell Anemia
Sickle-cell disease is a general term for a group of genetic disorders caused by sickle hemoglobin. In many forms of the disease, the red blood cells change shape, usually looking much like that of a banana, upon deoxygenation because of polymedrization of the abnormal sickle hemoglobin. This process damages the red blood cell membrane, and can cause the cells to become stuck in blood vessels. This deprives the downstream tissues of oxygen and causes ischemia and infarction. The disease is chronic and lifelong. Individuals are most often well, but their lives are punctuated by periodic painful attacks. In addition to periodic pain, there may be damage of internal organs, such as stroke. Lifespan is often shortened with sufferers living to an average of 40 years. Sickle-cell disease occurs more commonly in people from parts of the world, such as sub-Saharan Africa, where malaria is or was common, but it also occurs in people of other ethnicities.
Patients with sickle cell anemia can have symptoms that vary in severity, with typical hemoglobin levels of 6-9 g/dl. Reticulocyte counts are elevated, reflecting new red blood cells replacing the rapidly destroyed older cells - red blood cell life span is markedly reduced in this disease. Often, the white blood cell and platelet counts are elevated, and these cells may contribute to vaso-occlusion.
...More at Wikipedia
Related Links:
Sickle Cell Anemia
Questions recently asked by other users
Latest Blood / Hematology News From Medical News Today.
- New Biomarkers For Brain Tumor Discovered
- AspenBio Pharma Reports On FDA 510(k) Clinical Trial Progress For AppyScore, World's First Blood-Based Diagnostic Test For Human Appendicitis
- Contaminants In Life-Saving Drug Detected Using Simple New Method
- Burnet Prize Won By Benjamin Kile
- Pernicious Anaemia Awareness Week - "Needless Suffering Must Stop"
- Researchers Tackle CLL, Diabetes And Trauma-Hemorrhage - Molecular Medicine, A Bi-Monthly Journal
- Novel Oral Anticoagulant, ATI-5923, Promises Potential Benefits Over Leading Treatment
- Ferumoxytol Resubmission Designated Complete, Class 1 Response By FDA - Iron Deficiency Anemia In Chronic Kidney Disease Patients
- Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
- Case Of Patient "Cured" Of HIV Baffles Doctors
- Bone Marrow Toxicity In Advanced Lung Cancer May Be Reduced By Proton Therapy And Concurrent Chemotherapy
